CN114149506B

CN114149506B - anti-CD 22 antibody and application thereof

Info

Publication number: CN114149506B
Application number: CN202111545594.0A
Authority: CN
Inventors: 狄升蒙; 石磊; 余学军
Original assignee: Huadao Shanghai Biopharma Co ltd
Current assignee: Huadao Shanghai Biopharma Co ltd
Priority date: 2021-12-16
Filing date: 2021-12-16
Publication date: 2023-01-10
Anticipated expiration: 2041-12-16
Also published as: CN115925948A; CN115925948B; CN114149506A

Abstract

The invention discloses an anti-CD 22 antibody and application thereof. The anti-CD 22 antibody comprises a heavy chain variable region, wherein the amino acid sequence of CDR1 of the heavy chain variable region comprises the sequence shown in SEQ ID No.1 or SEQ ID No.2, the amino acid sequence of CDR2 of the heavy chain variable region comprises the sequence shown in SEQ ID No.3 or SEQ ID No.4, and the amino acid sequence of CDR3 of the heavy chain variable region comprises the sequence shown in SEQ ID No.5 or SEQ ID No. 6. The anti-CD 22 antibody has high affinity and specificity, can effectively target a tumor antigen CD22, prepares a chimeric antigen receptor by using the anti-CD 22 antibody, and further prepares chimeric antigen receptor cells, and the chimeric antigen receptor cells can kill tumor cells efficiently and have high specificity.

Description

anti-CD 22 antibody and application thereof

Technical Field

The invention belongs to the technical field of biological medicines, and relates to an anti-CD 22 antibody and application thereof.

Background

B-cell acute lymphoblastic leukemia (B-ALL) is an invasive hematological malignancy characterized by CD19 ⁺ Clonal expansion of B cell precursors. B-ALL is one of the most common malignancies in children, with a poor prognosis in adults, although less common. Although more than 90% of patients get complete remission after first-line treatment, the prognosis for refractory/relapsed (R/R) B-ALL patients is poor.

Adoptive transfer of artificial Chimeric antigen receptor T cells (CAR-T) engineered to express antigens associated with the surface of targeted tumor cells is revolutionaryCancer immune cell therapy. At present, CD19 CAR-T therapy is one of the ideal cell therapies for B-ALL, CD19 is uniformly expressed on malignant cells, whereas off-target expression is limited to normal B cells, and CD19 CAR-T induced B-cell dysgenesis is easily controlled clinically by using γ -immunoglobulin. CD19 CAR-T thoroughly changes the treatment of R/R B-ALL, and the complete remission rate reaches 80-90%; however, 40% to 60% of patients treated with CD19 targeted immunotherapy relapse after 1 year. The types of recurrence are mainly divided into two categories: one still being CD19 ⁺ Recurrence of (a), usually poor T cell function or short duration of CAR-T cells; another is the recurrence of CD19, whose disease is relapsed with loss of cell surface CD19 expression, representing a novel "stem cell origin-related" tumor escape mechanism.

Another promising target for CAR-T treatment of B-ALL is CD22.CD22 is a sialic acid binding adhesion molecule, the expression of which is primarily restricted to B cells and is highly expressed in most B cell malignancies. CD22 targeted immunotherapy has been developed and tested in several studies, for example CN111320703A discloses a CD22 targeted chimeric antigen receptor and its use, the chimeric antigen receptor sequence being selected from one of the following two structures, the first structure: a CD22 antigen binding domain and a constant domain of a T Cell Receptor (TCR); the second structure is as follows: a transmembrane protein signal peptide, a CD22 antigen binding domain, a hinge region of a CD8 protein molecule, a transmembrane region, a 4-1BB costimulatory domain and a CD3 zeta intracellular signaling domain in serial order; furthermore, in a study of children and young adult B-ALL patients who developed disease progression after CD19 CAR-T treatment, CD22 CAR-T induced a complete remission rate of 73%, which was specific for CD19 ⁺ And CD19 ^- B-ALL was equally effective. However, recurrence is also common, and a subset of patients have recurrence associated with down-regulation of CD22 expression. Therefore, R/R B-ALL remains clinically challenging.

In summary, the development of efficient CAR-T therapy for R/R B-ALL is of great significance in the field of B-ALL therapy.

Disclosure of Invention

Aiming at the defects and practical requirements of the prior art, the invention provides an anti-CD 22 antibody and application thereof, wherein the anti-CD 22 antibody has high affinity and specificity and can efficiently target CD22, and CAR-T cells constructed by taking the anti-CD 22 antibody as an antigen binding domain can efficiently target tumor cells CD22 so as to mediate immune cells to kill the tumor cells.

In order to achieve the purpose, the invention adopts the following technical scheme:

in a first aspect, the present invention provides an anti-CD 22 antibody, wherein the anti-CD 22 antibody comprises a heavy chain variable region, the amino acid sequence of CDR1 of the heavy chain variable region comprises the sequence shown in SEQ ID No.1 or SEQ ID No.2, the amino acid sequence of CDR2 of the heavy chain variable region comprises the sequence shown in SEQ ID No.3 or SEQ ID No.4, and the amino acid sequence of CDR3 of the heavy chain variable region comprises the sequence shown in SEQ ID No.5 or SEQ ID No. 6.

The anti-CD 22 antibody is screened, and the anti-CD 22 antibody only comprises a heavy chain variable region, has high affinity and specificity, can efficiently target a CD22 antigen, has a simple structure, is easy to prepare, and has important application value in the field of preparing medicaments taking CD22 as a target spot.

SEQ ID No.1：GDTHSSYC。

SEQ ID No.2：GYTNSRRY。

SEQ ID No.3：VDSDGKQ。

SEQ ID No.4：IYTGDGDSRT。

SEQ ID No.5：AAAPWCYREAEDFTI。

SEQ ID No.6：AADVWYHGDWNDPKLYPY。

Preferably, the amino acid sequence of CDR1 of the heavy chain variable region comprises the sequence shown in SEQ ID No.1, the amino acid sequence of CDR2 comprises the sequence shown in SEQ ID No.3, and the amino acid sequence of CDR3 comprises the sequence shown in SEQ ID No. 5.

Preferably, the amino acid sequence of CDR1 of the heavy chain variable region comprises the sequence shown in SEQ ID No.2, the amino acid sequence of CDR2 comprises the sequence shown in SEQ ID No.4, and the amino acid sequence of CDR3 comprises the sequence shown in SEQ ID No. 6.

Preferably, the heavy chain variable region further comprises framework regions FR1-FR4.

Preferably, the amino acid sequence of FR1 comprises the sequence shown in SEQ ID No.7 or SEQ ID No. 8.

Preferably, the amino acid sequence of FR2 comprises the sequence shown in SEQ ID No.9 or SEQ ID No. 10.

Preferably, the amino acid sequence of FR3 includes the sequence shown in SEQ ID No.11 or SEQ ID No. 12.

Preferably, the amino acid sequence of FR4 comprises the sequence shown in SEQ ID No. 13.

Preferably, the amino acid sequence of the heavy chain variable region comprises the sequence shown in SEQ ID No.14 or SEQ ID No. 15.

SEQ ID No.7：EVQLVESGGDSVQPGGSLRLSCAVS。

SEQ ID No.8：EVQLVESGGASVQAGGSLTLSCAAS。

SEQ ID No.9：LAWFRQAPGKEREGVAF。

SEQ ID No.10：MAWFRQTPGKEREGVAY。

SEQ ID No.11：

IHADSVKGRFTGSRDNTKNTLFLQMDSLQLEDTAMYYC。

SEQ ID No.12：

YYADSVKGRFTISRDNAKGTVNLQMNSLQPGDSAMYYC。

SEQ ID No.13：WGQGTQVTVSS。

SEQ ID No.14：

EVQLVESGGDSVQPGGSLRLSCAVSGDTHSSYCLAWFRQAPGKEREGVAFVDSDGKQIHADSVKGRFTGSRDNTKNTLFLQMDSLQLEDTAMYYCAAAPWCYREAEDFTIWGQGTQVTVSS。

SEQ ID No.15：

EVQLVESGGASVQAGGSLTLSCAASGYTNSRRYMAWFRQTPGKEREGVAYIYTGDGDSRTYYADSVKGRFTISRDNAKGTVNLQMNSLQPGDSAMYYCAADVWYHGDWNDPKLYPYWGQGTQVTVSS。

The coding gene of the anti-CD 22 antibody is inserted into an expression vector to obtain a recombinant expression vector, and the recombinant expression vector is introduced into cells and cultured, and then separated and purified to obtain the anti-CD 22 antibody.

In a second aspect, the present invention provides a nucleic acid molecule comprising a gene encoding the anti-CD 22 antibody of the first aspect.

Preferably, the nucleic acid molecule comprises the sequence shown as SEQ ID No.16 or SEQ ID No. 17.

SEQ ID No.16：

gaagtgcagctggtggaatctggcggcgatagcgtgcagcctggcggcagcctgagactgagctgtgccgtgagcggcgatacccatagcagctattgtctggcctggtttagacaggcccctggcaaagaaagagaaggcgtggcctttgtggattccgatggaaaacagattcatgccgatagcgtgaaaggccggtttaccggctccagagataataccaaaaataccctgtttctgcagatggatagcctgcagctggaagataccgccatgtattattgtgccgccgccccttggtgttatagagaagccgaagattttaccatttggggccagggcacccaggtgaccgtgagcagc。

SEQ ID No.17：

gaggtgcagctggtggagagcggcggcgccagcgtgcaggccggcggcagcctgaccctgagctgtgctgcctctggatacacaaattctagaagatatatggcctggtttagacagaccccaggaaaagagagagaaggcgtggcttatatctatacaggcgatggagattctagaacatattatgccgatagcgtgaagggcagattcacaattagcagagacaacgccaagggcaccgtgaacctgcagatgaacagcctgcagcccggcgacagcgccatgtactactgcgccgccgacgtgtggtaccacggcgactggaacgacccaaagctgtacccctactgggggcagggcacccaggtgaccgtgagcagc。

The nucleic acid molecule of the invention is capable of accurately encoding the anti-CD 22 antibody of the first aspect.

In a third aspect, the present invention provides a chimeric antigen receptor comprising a signal peptide, an antigen binding domain, a hinge region, a transmembrane domain, and a signaling domain, the antigen binding domain being the anti-CD 22 antibody of the first aspect.

In the invention, the anti-CD 22 antibody is used for constructing a chimeric antigen receptor which can efficiently target CD22.

Preferably, the signal peptide comprises a CD8a signal peptide.

Preferably, the antigen binding domain also includes an anti-CD19 antibody.

Preferably, the antigen binding domain comprises an antigen binding domain formed by connecting an anti-CD19 antibody and an anti-CD 22 antibody in series in sequence or an antigen binding domain formed by connecting an anti-CD 22 antibody and an anti-CD19 antibody in series in sequence.

Preferably, the hinge region comprises a CD8a hinge region;

preferably, the transmembrane region comprises any one of or a combination of at least two of a CD8a transmembrane region, a CD28 transmembrane region, or a DAP10 transmembrane region;

preferably, the signaling domain comprises an immunoreceptor tyrosine activation motif;

preferably, the signal transduction domain further comprises a co-stimulatory molecule comprising any one of the 4-1BB, CD28 intracellular domain, OX40, ICOS or DAP10 intracellular domain or a combination of at least two thereof

Preferably, the chimeric antigen receptor further comprises CD3 epsilon or CD3 gamma.

Preferably, the amino acid sequence of the signal peptide comprises the sequence shown in SEQ ID No. 18.

Preferably, the amino acid sequences of the CD8a hinge region and the transmembrane region comprise the sequence shown in SEQ ID No. 19.

Preferably, the amino acid sequence of the immunoreceptor tyrosine activation motif comprises a sequence shown as SEQ ID No. 20.

Preferably, the amino acid sequence of CD3 epsilon comprises the sequence shown in SEQ ID No. 21.

Preferably, the amino acid sequence of the CD3 gamma comprises the sequence shown in SEQ ID No. 22.

Preferably, the chimeric antigen receptor comprises a first peptide chain obtained by fusing an anti-CD19 antibody and a CD3 epsilon and a second peptide chain obtained by fusing an anti-CD 22 antibody and a CD3 gamma, or the chimeric antigen receptor comprises a first peptide chain obtained by fusing an anti-CD 22 antibody and a CD3 epsilon and a second peptide chain obtained by fusing an anti-CD19 antibody and a CD3 gamma.

In a fourth aspect, the present invention provides an expression vector comprising a gene encoding the chimeric antigen receptor of the third aspect.

Preferably, the expression vector is any one of a lentiviral vector, a retroviral vector or an adeno-associated viral vector containing the gene encoding the chimeric antigen receptor according to the third aspect, preferably a lentiviral vector.

In a fifth aspect, the present invention provides a recombinant lentivirus comprising the expression vector of the fourth aspect.

In the present invention, the recombinant lentivirus is prepared from mammalian cells transfected with the expression vector and helper plasmid of the fourth aspect.

In a sixth aspect, the present invention provides a chimeric antigen receptor immune cell expressing the chimeric antigen receptor of the third aspect.

The invention utilizes the anti-CD 22 antibody to prepare a chimeric antigen receptor and further prepare a chimeric antigen receptor immune cell, wherein the chimeric antigen receptor immune cell can specifically identify CD22 and/or CD19 positive tumor cells, can kill the cells efficiently, and can release various cell factors including IL-2, TNF-alpha, IFN-gamma factors and the like to play a role in killing the cells.

Preferably, the chimeric antigen receptor immune cell comprises the expression vector of the fourth aspect and/or the recombinant lentivirus of the fifth aspect.

Preferably, the immune cells comprise any one of T lymphocytes, B lymphocytes, NK cells, mast cells or macrophages or a combination of at least two thereof.

In a seventh aspect, the present invention provides a pharmaceutical composition comprising the chimeric antigen receptor immune cell of the sixth aspect.

Preferably, the pharmaceutical composition further comprises pharmaceutically acceptable excipients.

In an eighth aspect, the present invention provides the use of the anti-CD 22 antibody of the first aspect, the nucleic acid molecule of the second aspect, the chimeric antigen receptor of the third aspect, the expression vector of the fourth aspect, the recombinant lentivirus of the fifth aspect, the chimeric antigen receptor immune cell of the sixth aspect, or the pharmaceutical composition of the seventh aspect, in the preparation of a medicament for treating tumor.

Preferably, the tumor comprises B-cell acute lymphoblastic leukemia.

Compared with the prior art, the invention has the following beneficial effects:

(1) The anti-CD 22 antibody only comprises a heavy chain variable region, has high affinity and specificity, can efficiently target a CD22 antigen, and has a simple structure and easy preparation;

(2) In the invention, the anti-CD 22 antibody is used for constructing a chimeric antigen receptor which can efficiently target CD22, and in addition, an anti-CD 22 antibody and an anti-CD19 antibody can be simultaneously adopted as an antigen binding domain, so that the chimeric antigen receptor which can simultaneously target CD22 and CD19 is prepared;

(3) The chimeric antigen receptor cell can specifically recognize CD22 and/or CD19 positive tumor cells, kill the cells efficiently, and release various cytokines including IL-2, TNF-alpha, IFN-gamma factors and the like to play a role in killing the cells.

Drawings

FIG. 1A is a graph showing the result of Biacore's affinity assay for anti-CD 22 antibody (CD 22-28);

FIG. 1B is a graph showing the results of Biacore's affinity assay for anti-CD 22 antibody (CD 22-29);

FIG. 2 is a graph showing the results of FACS detection of CD22 antigen on the cell surface recognized by anti-CD 22 antibody;

FIG. 3A is a plasmid map of a lentiviral vector expressing a chimeric CD22 antigen receptor (HD SIN03 CD22 (V28) 41BBz (ka));

FIG. 3B is a plasmid map of a lentiviral vector expressing a chimeric CD22 antigen receptor (HD SIN03 CD22 (V29) 41BBz (ka));

FIG. 3C is a plasmid map of a lentiviral vector expressing a chimeric CD22 antigen receptor (HD SIN03 CD19-CD22 (V28) 41BBz (ka));

FIG. 3D is a plasmid map of a lentiviral vector expressing a chimeric CD22 antigen receptor (HD SIN03 CD19-CD22 (V29) 41BBz (ka));

FIG. 3E is a plasmid map of a lentiviral vector expressing a chimeric CD22 antigen receptor (HD SIN03 CD22 (V28) -CD19-41BBz (ka));

FIG. 3F is a plasmid map of a lentiviral vector expressing a chimeric CD22 antigen receptor (HD SIN03 CD22 (V29) -CD19-41BBz (ka));

FIG. 3G is a plasmid map of a lentiviral vector expressing a chimeric CD22 antigen receptor (HD SIN03 CD19-CD3 ε -T2A-CD22 (V28) -CD3 γ (ka));

FIG. 3H is a plasmid map of a lentiviral vector expressing a chimeric CD22 antigen receptor (HD SIN03 CD19-CD3 ε -T2A-CD22 (V29) -CD3 γ (ka));

FIG. 4A is a schematic diagram of the structure of a CD22 chimeric antigen receptor (antigen binding domain containing only CD22 antibody);

FIG. 4B is a schematic diagram of the structure of the CD22 chimeric antigen receptor (CD 19 antibody before CD22 antibody);

FIG. 4C is a schematic diagram of the structure of the CD22 chimeric antigen receptor (CD 19 antibody after CD22 antibody);

FIG. 4D is a schematic diagram of the structure of the CD22 chimeric antigen receptor (CD 19 antibody precedes CD22 antibody and is linked to CD3 ε -T2A);

FIG. 5 is a graph of chimeric antigen receptor expression rates in CAR-T cells;

FIG. 6A is a graph showing the killing effect of CAR-T cells of the present invention on K562-luci cells;

FIG. 6B is a graph showing the killing effect of the CAR-T cells of the present invention on K562-CD19-luci cells;

FIG. 6C is a graph showing the killing effect of CAR-T cells of the present invention on K562-CD22-luci cells;

FIG. 6D is a graph showing the killing effect of CAR-T cells of the present invention on K562-CD19-CD22-luci cells;

FIG. 7 is a graph of IL-2 cytokine secretion levels by CAR-T cells;

FIG. 8 is a graph of TNF-alpha cytokine secretion levels by CAR-T cells;

FIG. 9 is a graph of the IFN- γ cytokine secretion levels of CAR-T cells.

Detailed Description

To further illustrate the technical means adopted by the present invention and the effects thereof, the present invention is further described below with reference to the embodiments and the accompanying drawings. It is to be understood that the specific embodiments described herein are merely illustrative of the invention and are not limiting of the invention.

The examples do not show the specific techniques or conditions, according to the technical or conditions described in the literature in the field, or according to the product specifications. The reagents or apparatus used are conventional products commercially available from normal sources, not indicated by the manufacturer.

In the invention, a phage display technology is utilized to screen a VHH immune library of the alpaca immunized by the CD22, so that the nano antibody with high affinity and CD22 resistance is obtained.

Example 1

In this example, phage nanobody library was constructed and panning and ELISA primary screening were performed.

1. Construction of phage Nanobody libraries

(1) Adopting CD22-Fc expressing an extracellular region to immunize bactrian camel, and extracting 200mL of peripheral blood after the titer is verified by ELISA;

(2) Sorting lymphocytes to obtain peripheral blood mononuclear lymphocyte sediment and extracting RNA;

(3) By using

III, synthesizing first strand cDNA by using reverse transcriptase with RNA as a template, and then amplifying a VHH gene by using nested PCR;

(4) Inserting VHH gene into pMECS phage display carrier, after electrotransformation of TG1 competent cell, taking bacterial liquid to perform library identification, uniformly coating the rest culture on LB/AMPGLU flat plate, collecting lawn after bacterial growth, adding 50% glycerol with 1/3 volume, uniformly mixing and packaging, storing at-80 ℃, successfully constructing the product with the storage capacity of more than 10 ⁹ The phage display camelid VHH immune library of (a).

2. Panning of phage Nanobody libraries

Diluting the purified CD22-His recombinant protein to 4 mu g/mL by using a PBS buffer solution, taking a 96-well enzyme label plate, selecting 3 wells, adding 100 mu L (400 ng/well) into each well, coating overnight at 4 ℃, and using the PBS as a negative control; discarding the coating solution, adding 150 μ L of 2% defatted inner powder into each well, and sealing at 25 deg.C for 1 hr; washing with PBST for 4 times, taking the prepared phage solution, diluting to 5 × 1011pfu/ml with 2% milk powder, adding an enzyme-labeled plate, 100 μ L/hole, and incubating at 25 deg.C for 2h; discarding the phage sample, washing with PBST for 10 times, then washing with PBS for 5 times, adding 100 μ L freshly prepared 0.1M triethylamine to each well, standing at 25 deg.C for 10min, sucking out the eluate, and rapidly using the same volume1M Tris-HCl (pH7.4) neutralization; taking part of the eluent to determine the titer of the phage; taking 400 μ L of eluate, infecting 4mL of fresh logarithmic phase TG1 bacterial solution (OD 600 about 0.6), incubating at 37 deg.C for 30min, adding 16mL of 2 XYT/AMP-GLU, culturing at 37 deg.C and 200r/min to OD ₆₀₀ Up to 0.7. Taking 100 mu L of bacterial suspension, performing gradient dilution, and uniformly smearing the bacterial suspension on a2 XYT/ampicillin/glucose agar plate so as to perform library capacity and diversity determination; inoculating 100 μ L bacterial suspension, namely phage display carrier library, into a2 XYT/AMP-GLU culture medium, culturing to logarithmic phase, adding auxiliary phage, performing library rescue, obtaining phage titer to be measured of phage particles, and concentrating and purifying to obtain phage particles for next round of screening; the rest bacteria liquid is centrifuged and then resuspended by 2 XYT culture solution with proper volume, smeared on a plate with screening resistance for overnight culture, scraped from the plate by proper liquid culture solution, added with 2 XYT culture solution containing 50% glycerol with 1/3 volume for resuspension and subpackaged, and all the bacteria are preserved at-80 ℃.

The above screening operation was repeated 3 times.

3 rounds of solid phase screening are carried out on the immune nano antibody library in vitro, so that phage clones with binding activity are effectively enriched. After prokaryotic induction expression is carried out on the monoclonal phage, phage clones capable of combining with the extracellular region of the antigen are further screened out by ELISA.

3. Phage packaging

100 μ L of the frozen stock solution from the previous round was added to 100mL of 2 XYT/AMPGL culture solution and cultured at 37 deg.C with shaking (200 rpm) until logarithmic phase (OD) ₆₀₀ Value 0.6), 90. Mu.L of the helper phage M13K07 (1.7X 10) was added ¹³ PFU/mL), the mixture is firstly kept still at 37 ℃ for 30min,2800 Xg is centrifuged for 10min to collect thalli, then the thalli is resuspended by 200mL of 2 XYT/AMP-KAN culture medium, shaking (200 rpm) at 37 ℃ is cultured for 12h,4 ℃ and 3800 Xg are centrifuged for 30min to remove thalli and collect supernatant, 1/5 volume of precooled PEG/NaCl is added for mixing, phage is precipitated for 2h,4 ℃ and 3800 Xg are centrifuged for 30min to collect phage, then the phage is resuspended by final volume of 2mL of PBS solution and transferred to a 15mL centrifuge tube, 4 ℃ and 12000 Xg is centrifuged for 15min to collect supernatant, 1/5 volume of precooled PEG/NaCl solution is added,turning upside down and mixing evenly, and standing for 2h on ice; centrifuging at 4 deg.C and 10000 Xg for 10min, discarding supernatant, resuspending phage precipitate with 1mL PBS, incubating overnight at 4 deg.C with shaking table to dissolve phage particles completely, mixing phage solution with equal volume of 60% glycerol, packaging into 1.5mL EP tube, and storing at-80 deg.C.

And 3 rounds of panning on the phage library by using CD22 antigen, in order to avoid losing sequence diversity, primary ELISA screening is carried out on panning products of 2 nd round and 3 rd round, positive clones are randomly selected from the panning products and are induced to express, an expression supernatant is a crude VHH antibody, and the VHH antibody sequence of a monoclonal strain is determined by sequencing.

Example 2

This example performs Fluorescence Activated Cell Sorting (FACS) candidate clones.

Nalm6 (CD 22) was cultured according to standard cell culture protocols ⁺ )、Raji(CD22 ⁺ )、K562(CD22 ^- ) (both available from ATCC) and SK-hep-1 (CD 22) ^- Purchased from shanghai cell bank of chinese academy of sciences), CD22 positive and negative cell suspensions were prepared using trypsinized cells, centrifuged (300 × g,5 min) to remove the culture medium and the cells were resuspended to 2 × 10 using Flow Buffer ⁶ cell/mL, V-bottom 96-well plate 2X 10 addition per well ⁵ Cell suspension of individual cells, centrifugation at 300 Xg for 5min to remove supernatant, adding VHH antibody crude extract to resuspend cells, and incubation at 4 ℃ for 1h, centrifugation at 300 Xg for 5min to remove supernatant, flow Buffer to resuspend cells, using Flow Buffer to dilute APC anti-his antibody to 2. Mu.g/mL, resuspend cells at 100. Mu.L per well, incubation at 4 ℃ for 1h, flow Buffer to wash cells for 3 times, then using 200. Mu.L Flow Buffer to resuspend cells and detecting by up-Flow cytometry, and screening two candidate antibodies, named CD22-28 and CD22-29.

Example 3

This example performs VHH-mIgG2a Fc nanobody expression, purification, and antibody affinity determination.

In order to further identify the antibodies screened in example 2, it is necessary to express the antibodies in mammalian cells, and therefore, a plasmid vector C-4pcp.stuffer-mCg2a-Fc with a mouse Fc tag expressing VHH was first constructed, the construction method comprising the following steps:

(1) PCR amplification of CD22 VHH: CD22-28 and CD22-29, the reagents used are shown in Table 1, the primers are shown in Table 2, and the system and PCR conditions are shown in Table 3;

TABLE 1

TABLE 2

TABLE 3

(2) The digestion system and reaction conditions are shown in Table 4, respectively, for the digested vector

Purifying by using a PCR purification kit, dissolving the air-dried DNA into 20 mu L of water, and detecting the concentration of the DNA;

TABLE 4

(3) The homologous recombination reaction system was 10. Mu.L, as shown in Table 5;

TABLE 5

(4) Adding all homologous recombination reaction systems into DH5 alpha competent cells, and transforming the DH5 alpha competent cells under the transformation conditions shown in Table 6;

TABLE 6

(5) Selecting monoclonal PCR for pre-identification by the transformation plate, wherein the conditions of a PCR identification system are shown in Table 7; sending the vector to a sequencing company for sequencing identification, wherein the sequencing result is in accordance with expectation, and successfully constructing the plasmid vector with the mouse Fc tag expression VHH.

TABLE 7

293E cells were passaged to a cell density of about 2.6X 10 approximately 24h prior to plasmid transfection ⁶ cells/mL, 0.15mg scFV-mIgG1/100mL 293E was transfected into 293E cells by PEI method, DNA: PEI = 1. 37 ℃, 130rpm, 8% CO ₂ Shaking culture for 6 days, collecting cell culture supernatant at 3000rpm,30min, filtering the collected supernatant containing the target antibody with Millex-GP Filter Unit 0.45 μm Sterile, and selecting with MabSelect ^TM SuRe ^TM After concentration by centrifugation, the column was washed with 1 XPBS, the protein eluted with 0.1M (mol/L) Gly-HCl and neutralized with 1/10 volume of Tris-HCl pH 8.5, and dialyzed overnight at 4 ℃ for protein, quantified by the method of A280 assay by NanoDrop 2000, and the antibody purity was determined by SEC-HPLC.

In addition, affinity determination was performed by Biacore on the purified 2 CD22 VHH antibodies (CD 22-28 and CD 22-29). Biacore is a bioanalytical sensing technology developed based on Surface Plasmon Resonance (SPR), and can detect and track the whole process of binding and dissociation of molecules in a solution to and from a molecule immobilized on a chip surface, record the whole process in the form of a sensorgram, and provide kinetic and affinity data, in the process of measurement, antibodies are immobilized on the chip surface, a mobile phase is a solution containing antigens, and the measurement results are shown in table 8 and fig. 1A and 1B, and it is known from the measurement results that these 2 kinds of CD22 VHH antibodies have high affinity.

TABLE 8

Stationary phase	Mobile phase	ka(1/Ms)	kd(1/s)	KD(M)
					0.5μg/mL CD22-28	CD22	2.79E+05	1.44E-04	5.14E-10
0.5μg/mL CD22-29	CD22	2.16E+05	1.88E-05	8.68E-11

Example 4

This example was performed by flow assay of anti-CD 22 single chain antibody.

Nalm6 tumor cells and purified 2 strains of recombinant anti-CD 22 VHH-mIgG2 antibodies (CD 22-28 and CD 22-29) are incubated for 30min in ice bath, a blank control group is not added with the anti-CD 22 VHH-mIgG2 antibodies, then the cells are incubated for 30min with APC-labeled goat anti-mouse IgG antibodies, and the detection is carried out by a flow cytometer, and the result is shown in FIG. 2, which indicates that the anti-CD 22 antibodies prepared by screening can recognize CD22 antigens on the cell surfaces.

Example 5

This example prepares lentiviral vectors expressing a chimeric antigen receptor for an anti-CD 22 antibody (CD 22 VHH) and a chimeric antigen receptor co-expressing CD22 VHH and CD19 scFv.

Construction of lentiviral vectors HD SIN03 CD22 (V28) 41BBz (ka) and HD SIN03 CD22 (V29) 41BBz (ka) carrying chimeric antigen receptors for CD22 VHH (CD 22-28 and CD 22-29), and 6 lentiviral vectors also carrying simultaneously CD19 antibodies:

HD SIN03 CD19-CD22 (V28) 41BBz (ka) and HD SIN03 CD19-CD22 (V29) 41BBz (ka), with the CD19 antibody preceding the CD20 antibody;

HD SIN03 CD22 (V28) -CD19-41BBz (ka) and HD SIN03 CD22 (V29) -CD19-41BBz (ka), CD19 antibody after CD20 antibody;

HD SIN03 CD19-CD3 epsilon-T2A-CD 22 (V28) -CD3 gamma (ka) and HD SIN03 CD19-CD3 epsilon-T2A-CD 22 (V29) -CD3 gamma (ka), with the CD19 antibody preceding the CD20 antibody and with CD3 epsilon-T2A attached in between;

the vector maps are shown in FIGS. 3A-3H, and the chimeric antigen receptor containing a signal peptide, CD22 VHH, CD19 scFv, CD8 alpha hinge region, transmembrane region, immunoreceptor tyrosine activation motif, CD3 epsilon or CD3 gamma is expressed, and the structural schematic diagram of the chimeric antigen receptor is shown in FIGS. 4A-4D.

1. Construction of HD SIN03 CD22 (V28) 41BBz (ka) and HD SIN03 CD22 (V29) 41BBz (ka) Lentiviral vectors

1. A PCR reaction system was prepared according to Table 10, and the CD22 VHH fragment was amplified using the primers shown in Table 9.

TABLE 9

Note: CD22 (28) -R may be substituted for CD22 (29) -R.

TABLE 10

Reagent	Volume (μ L)
		10 Xbuffer	5
2mM dNTP	5
		25mM MgSO ₄	3
10μM primer F	1
		10μM primer R	1
Template DNA(cDNA clone)	1
		PCR-grade pure water	33
KOD-Plus-Neo	1

The above reagent is from TOYOBO Inc.

After preparation, the reaction was carried out according to the PCR procedure shown in Table 11.

TABLE 11

2. A PCR reaction system was prepared according to Table 13, and a signal peptide was added to the antibody fragment, and the amino acid sequence of the signal peptide is shown in Table 12 using primers: MALPHVTALLLPLALLLHAARP (SEQ ID No. 18).

TABLE 12

Note: CD22 (28) -R may be substituted for CD22 (29) -R.

Watch 13

After the preparation, PCR reaction was carried out according to the PCR procedure shown in Table 11, after the reaction was completed, the PCR product was subjected to 1% agarose gel electrophoresis, and fragments of about 500bp were recovered and quantified by an ultraviolet absorption method.

3. PCR reaction systems were prepared according to Table 14, and the CD8a hinge-TM-41BB-CD3Z fragments were amplified using the following primers:

CD8aH-F：accacgacgccagcgccgcgac。

Vector-R：tcgataagcttgatatcg。

after the preparation, PCR reaction was carried out according to the PCR procedure shown in Table 11, after the PCR was finished, 1% agarose gel electrophoresis was carried out, and fragments of about 780bp were recovered and quantified by UV absorption.

TABLE 14

Reagent	Volume (mu L)
		10 Xbuffer	5
2mM dNTP	5
		25mM MgSO ₄	3
10μM primer F CD8aH-F	1
		10μM primer R Vector-R	1
Template DNA (HD CD19 CAR)	1
		PCR-grade pure water	33
KOD-Plus-Neo	1

The reagent is from TOYOBO Inc.

4. Mu.g of the constructed HD SIN03 CD19 BBz (ka) plasmid was digested with BamHI and EcoRI, reacted in a water bath at 37 ℃ for 2 hours, and then the vector was recovered.

5. Connecting the 2 fragments recovered in the

steps

2 and 3 with the vector obtained in the step 4 by using recombinase, wherein a recombination reaction system is shown in table 15, reacting in water bath at 37 ℃ for 0.5h after the preparation is finished, transforming to escherichia coli stbl3 competent cells by a conventional method, selecting monoclone from a solid culture medium, culturing overnight, carrying out PCR identification, preparing a PCR reactant as shown in a graph 16, carrying out PCR program as shown in table 17, selecting positive clone after the PCR is finished for further sequencing identification, and obtaining a sequencing result which is in line with the expectation.

Watch 15

Reagent	Dosage of
		HD SIN03 CD19 41BBz(ka)	150ng
CD8a signal CD22 VHH	15ng
		CD8a hinge-TM-41BB-CD3Z	15ng
5x CE MultiS buffer	2μL
		Exnase MultiS	1μL
PCR-grade pure water	Up to 10μL
		Total volume	10μL

TABLE 16

Reagent	Volume (mu L)
		Taq PCR Master Mix	10
10μM F Seq-trEF1a-F	1
		10μM R Vector-R	1
Template DNA bacterial liquid	1
		PCR-grade pure water	7
Total volume	20

TABLE 17

The amino acid sequences of the CD22 VHH 2 clones (CD 22-28, CD22-29) are shown as SEQ ID No.14 and SEQ ID No. 15.

The amino acid sequences of the CD8 α hinge and transmembrane regions are:

TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC(SEQ ID No.19)。

the amino acid sequence of the immunoreceptor tyrosine activation motif is:

RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID No.20)。

the nucleotide sequence of the CD22 VHH is shown as SEQ ID No.16 and SEQ ID No. 17.

2. Construction of HD SIN03 CD19-CD22 (V28) 41BBz (ka) and HD SIN03 CD19-CD22 (V29) 41BBz (ka) Lentiviral vectors

1. The PCR reaction system shown in Table 18 was prepared using HD SIN03 CD1941BBz (ka) as a template, and CD8a leader-CD19 scFv fragments were amplified. The primers used were as follows:

BamH-CD8a sig-F：

GCTGCAGGTCGACTCTAGAGGATCCCGCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGC。

Linker(75)-CD19VH-R：

CACCCGATCCGCCGCCCCCAGATCCGCCCCCACCGGACCCTCCACCGCCTGAACCGCCCCCTCCTGAGGAGACGGTGACTGAG。

after the preparation, PCR reaction was carried out according to the PCR procedure shown in Table 19, after the PCR was completed, 1% agarose gel electrophoresis was carried out, and fragments of about 800bp were recovered and quantified by ultraviolet absorption.

Watch 18

Reagent	Volume (mu L)
		10x buffer	5
2mM dNTP	5
		25mM MgSO ₄	3
10μM primer F	1
		10μM primer R	1
Template DNA	1
		PCR-grade pure water	33
KOD-Plus-Neo	1

Watch 19

2. The PCR reaction systems in Table 18 were prepared using HD SIN03 CD22 (V28) 41BBz (ka) and HD SIN03 CD22 (V29) 41BBz (ka) as templates, respectively, to amplify fragments of CD22 (V28) -CD8a hinge-TM-41BB-CD3Z and CD22 (V29) -CD8a hinge-TM-41BB-CD3Z, using the following primers:

Linker(75)-CD22(V28)-F：

GGCGGCGGATCGGGTGGTGGTGGTAGTGAAGTGCAGCTGGTGGAATC；

Vector-R：TCGATAAGCTTGATATCG；

Linker(75)-CD22(V29)-F：

GGCGGCGGATCGGGTGGTGGTGGTAGTGAGGTGCAGCTGGTGGAG；

Vector-R：TCGATAAGCTTGATATCG。

after the preparation, PCR reaction was carried out according to the PCR procedure shown in Table 19, after the PCR was completed, 1% agarose gel electrophoresis was carried out, and fragments of about 1100bp were recovered and quantified by an ultraviolet absorption method.

3. Connecting the 2 fragments with the vector obtained in the first step and the second step by using recombinase, wherein a recombination reaction system is shown in table 20, reacting in water bath at 37 ℃ for 0.5h after the preparation is finished, transforming the recombinant vector into escherichia coli stbl3 competent cells by a conventional method, selecting monoclone from a solid culture medium, culturing overnight, carrying out PCR identification, selecting positive clone after the PCR is finished, further sequencing and identifying, wherein the sequencing result is in line with expectation, the PCR reactant preparation is shown in table 16, and the PCR program is shown in table 17.

Watch 20

3. Construction of HD SIN03 CD22 (V28) -CD19 BBz (ka) and HD SIN03 CD22 (V29) -CD19 BBz (ka) Lentiviral vectors

1. The PCR reaction system of Table 18 was prepared using HD SIN03 CD19 BBz (ka) as a template to amplify a CD19 scFv-CD8a hinge-TM-41BB-CD3Z fragment using the following primers:

Linker(75)-CD19VL-F：

GGCGGCGGATCGGGTGGTGGTGGTAGTGACATCCAGATGACACAG；

Vector-R：TCGATAAGCTTGATATCG；

after the preparation, PCR reaction was carried out according to the PCR procedure shown in Table 19, after the PCR was completed, 1% agarose gel electrophoresis was carried out, and a fragment of about 1400bp was recovered and quantified by an ultraviolet absorption method.

2. The PCR reaction system of Table 18 was prepared using HD SIN03 CD22 (V28) 41BBz (ka) and HD SIN03 CD22 (V29) 41BBz (ka) as templates, respectively, to amplify the CD8a leader-CD22 (V28) VHH and CD8a leader-CD22 (V29) VHH fragments using the primers as follows:

BamH-CD8a sig-F：

GCTGCAGGTCGACTCTAGAGGATCCCGCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGC；

Linker(75)-CD22(V28)-R：

CACCCGATCCGCCGCCCCCAGATCCGCCCCCACCGGACCCTCCACCGCCTGAACCGCCCCCTCCGCTGCTCACGGTCACCTG；

BamH-CD8a sig-F：

GCTGCAGGTCGACTCTAGAGGATCCCGCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGC；

Linker(75)-CD22(V29)-R：

after the preparation, PCR reaction was carried out according to the PCR procedure shown in Table 19, after the PCR was completed, 1% agarose gel electrophoresis was carried out, and fragments of about 500bp were recovered and quantified by an ultraviolet absorption method.

3. Connecting the 2 fragments with the vector obtained in the first step and the first step by using recombinase, wherein a recombination reaction system is shown in table 21, reacting in water bath at 37 ℃ for 0.5h after the preparation is finished, transforming the mixture into escherichia coli stbl3 competent cells by a conventional method, selecting monoclone from a solid culture medium, culturing overnight, carrying out PCR identification, preparing a PCR reactant as shown in a graph 16, carrying out PCR program as shown in table 17, selecting positive clone after the PCR is finished, further sequencing and identifying, and the sequencing result is in line with the expectation.

TABLE 21

Reagent	Amount of the composition
		HD SIN03 CD19 41BBz(ka)	150ng
CD19 scFv-CD8a hinge-TM-41BB-CD3Z	28ng
		CD8a leader-CD22 (V28 or V29)	10ng
5x CE MultiS buffer	2μL
		Exnase MultiS	1μL
PCR-grade pure water	Adding to 10 μ L
		Total volume	10μL

4. Construction of HD SIN03 CD19-CD3 epsilon-T2A-CD 22 (V28) -CD3 gamma (ka) and HD SIN03 CD19-CD3 epsilon-T2A-CD 22 (V29) -CD3 gamma (ka) Lentiviral vectors

1. The PCR reaction system of Table 18 was prepared using HD SIN03 CD19 BBz (ka) as a template to amplify the CD8a leader-CD19 scFv fragment using the following primers:

BamH-CD8a sig-F：

GCTGCAGGTCGACTCTAGAGGATCCCGCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGC；

Linker3-CD19VH-R：

AGATCCGCCCCCACCGGACCCTCCACCGCCTGAACCGCCCCCTCCTGAGGAGACGGTGACTGAG；

after the preparation, PCR reaction was carried out according to the PCR procedure shown in Table 19, after the PCR was finished, 1% agarose gel electrophoresis was carried out, and fragments of about 800bp were recovered and quantified by an ultraviolet absorption method.

2. A PCR reaction system of Table 18 was prepared using pUC57-CD 3. Epsilon. Expression vector biosynthesized in the Venetian institute of technology as a template to amplify the CD 3. Epsilon. Fragment using the following primers:

Linker3-CD3ε-ECD-F：

CGGTGGGGGCGGATCTGATGGTAATGAAGAAATGG；

T2A-CD3ε-ICD-R：

AGGGCCGGGATTCTCCTCCACGTCACCGCATGTTAGAAGACTTCCTCTGCCCTCGATGCGTCTCTGATTCAG；

after the preparation, PCR reaction was carried out according to the PCR procedure shown in Table 19, after the PCR was completed, 1% agarose gel electrophoresis was carried out, and a fragment of about 600bp was recovered and quantified by an ultraviolet absorption method.

3. The PCR reaction systems in Table 18 were prepared using HD SIN03 CD22 (V28) 41BBz (ka) and HD SIN03 CD22 (V29) 41BBz (ka) as templates, respectively, to amplify CD8a leader-CD22 (V28) and CD8a leader-CD22 (V29) fragments using the following primers:

T2A-CD8a sig-F：GGAGAATCCCGGCCCTATGGCCTTACCAGTGACC；

Linker2-CD22(V28)-R：

AGAGCCACCACCTCCGGAGCCGCCACCTCCGGACCCTCCGCCACCGCTGCTCACGGTCACCTG；

T2A-CD8a sig-F：GGAGAATCCCGGCCCTATGGCCTTACCAGTGACC。

Linker2-CD22(V29)-R：

AGAGCCACCACCTCCGGAGCCGCCACCTCCGGACCCTCCGCCACCGCTGCTCACGGTCACCTG；

after the preparation, PCR reaction was carried out according to the PCR procedure shown in Table 19, after the completion of PCR, 1% agarose gel electrophoresis was carried out, and fragments of about 500bp were recovered and quantified by an ultraviolet absorption method.

4. The PCR reaction system of table 18 was configured using pUC57-CD3 γ expression vector biosynthesized by entrustom as a template, and CD3 γ fragments were amplified using the following primers:

Linker2-CD3γ-ECD-F：

CGGAGGTGGTGGCTCTCAGTCAATCAAAGGAAACC；

EcoRI-CD3γ-ICD-R：

TCGATAAGCTTGATATCGAATTCTCAATTCCTCCTCAACTGG；

5. The 4 fragments and the vector obtained in the first step.4 are connected by recombinase, the recombination reaction system is shown in Table 22, the prepared vector is reacted in water bath at 37 ℃ for 0.5h, and the prepared vector is transformed into escherichia coli stbl3 competent cells according to a conventional method. Selecting single clone from a solid culture medium, culturing overnight, performing PCR identification, preparing PCR reactants as shown in a table 16, performing PCR program as shown in a table 17, selecting positive clone after PCR is finished, further sequencing identification, and ensuring that the sequencing result is in line with expectation.

TABLE 22

Reagent	Dosage of
		HD SIN03 CD19 41BBz(ka)	150ng
CD8a leader-CD19 scFv	16ng
		CD3ε	12ng
CD8a leader-CD22 (V28 or V29)	10ng
		CD3γ	10ng
5x CE MultiS buffer	2μL
		Exnase MultiS	1μL
PCR-grade pure water	Adding to 10 μ L
		Total volume	10μL

6. Separating the obtained signal peptide-VHH, CD19 scFv-CD8a hinge-TM-41BB-CD3Z, CD22 (V28 or V29) -CD8a hinge-TM-41BB-CD3Z, signal peptide-CD 19 scFv, CD3 epsilon and CD3 gamma fragments by agarose gel electrophoresis, and then recovering, purifying and quantifying by using an agarose gel DNA fragment recovery kit; the lentiviral expression vector HD SIN03 CD19 BBz (ka) was cut with the restriction enzymes BamHI and EcoRI (from NEB) and the procedure was performed as described. Separating the enzyme digestion product by agarose gel electrophoresis, and then recovering, purifying and quantifying by using an agarose gel DNA fragment recovery kit; then cloning the corresponding target fragment and the vector into a lentiviral vector by using a recombinase, and carrying out sequencing verification, wherein the sequencing result is in line with expectation.

The amino acid sequence of the CD3 epsilon fragment is (SEQ ID No. 21):

DGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDVMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERPPPVPNPDYEPIRKGQRDLYSGLNQRRI。

the amino acid sequence of the CD3 gamma fragment is (SEQ ID No. 22):

QSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLFAEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLRRN。

example 6

This example performed lentiviral packaging, comprising the steps of:

(1) At 1.6X 10 ⁷ Cell number 293T cells plated in 15cm dishes at 37 ℃ C. And 5% CO ₂ Culturing overnight to prepare packaged virus, wherein the culture medium is DMEM and 10% Fetal Bovine Serum (FBS) is added;

(2) Dissolving 30 μ g of the 8 lentiviral vectors constructed in example 5, 12.5 μ g of helper plasmid gag/pol and 10 μ g of envelope plasmid VSVg in 2000 μ L of serum-free DMEM culture solution, and mixing;

(3) Mu.g PEI (1. Mu.g/. Mu.L) was dissolved in 2000. Mu.L serum-free DMEM medium, vortexed at 1000rpm for 5 seconds, and incubated at 25 ℃ for 5min;

(4) Formation of transfection complexes: adding the PEI mixed solution into the DNA mixed solution, immediately carrying out vortex mixing or lightly mixing after adding, and incubating for 20min at 25 ℃;

(5) 4mL of the transfection compound is dripped into a 15cm culture dish containing 25mL of DMEM culture medium, and after 4 hours, the fresh culture medium is replaced;

(6) After 48h, collecting the virus liquid supernatant to obtain 8 lentiviruses expressing chimeric antigen receptors with different structures.

Example 7

This example was performed for lentivirus concentration.

Filtering the virus supernatant prepared in example 6 by using a 0.45-micron filter membrane, collecting the filtered virus supernatant into a 50mL centrifuge tube, adding 1/4 of PEG-NaCl virus concentrated solution, reversing the mixture up and down, uniformly mixing the mixture, and standing the mixture at 4 ℃ overnight; centrifuging at 4 deg.C and 3500rpm for 30min; removing supernatant, adding RPMI 1640 medium (containing 10% FBS), and dissolving the heavy suspension virus precipitate; the concentrated lentiviral suspension was aliquoted into 50 μ L aliquots, stored in finished tubes and stored at-80 ℃.

Example 8

This example performs a lentivirus titer test.

500. Mu.L of K562 cells (1X 10) ⁵ Individual cells) were seeded into 24-well culture plates; the concentrated lentivirus of example 7 was added to the cell suspension at 1. Mu.L, 0.2. Mu.L and 0.04. Mu.L, respectively, and polybrene was added to a final concentration of 5. Mu.g/mL; 37 ℃,5% of CO ₂ After overnight culture, the fresh medium was replaced; after 72h of infection, 400 Xg centrifugation for 5min, abandoning supernatant collected cells, adding 100. Mu.L PBS +2% FBS heavy suspension cells, adding 1. Mu.g AF488-anti-CD19 scFv and/or PE-anti-VHH antibody, ice incubation for 30min; after washing 2 times with PBS +2 fbs, 300 μ L of PBS +2% fbs-resuspended cells were added, and infection efficiency was measured with flow cytometry; taking a cell sample with a positive rate of 15%, calculating titer (TU/mL) = cell number (10) ⁵ ) X positive rate/virus volume (mL).

Example 9

This example utilizes lentiviruses to transduce T lymphocytes.

Diluting anti-human CD3 antibody and anti-human CD28 antibody with PBS (phosphate buffer solution) to final concentrations of 1 mug/mL and 0.5 mug/mL respectively, coating a pore plate, and standing in a refrigerator at 4 ℃ overnight; discarding the antibody coating solution in the pore plate, and washing twice with 1mL of PBS; FBS + IL-2 (300U +) with T cell medium (X-VIVO +10%mL)) human PBMC were adjusted to a density of 1X 10 ⁶ mL, then inoculated into CD3 and CD28 antibody coated well plates for activation for 48h; collecting activated T cells, adjusting cell density to 1 × 10 ⁶ (ii)/mL, adding lentivirus prepared in example 7 at multiplicity of infection (MOI) =10, adding polybrene to a final concentration of 5 μ g/mL; at 37 ℃ C, 5% CO ₂ After overnight incubation in the environment, the medium was replaced with fresh medium and passaged every 2 days.

Example 10

This example performed T lymphocyte chimeric antigen receptor expression, comprising the steps of:

(1) After 5 days of infection, 3X 10 of the above-mentioned three-dimensional samples were taken ⁵ Centrifuging the T cells at 4 ℃ at 400 Xg for 5min, discarding the supernatant, and washing the cells once with PBS +2% FBS;

(2) Add 100. Mu.L PBS +2% FBS resuspended cells, add 1. Mu.g AF488-anti-CD19 scFv and PE-anti-VHH antibody, incubate on ice for 30min; after 2 times of PBS + 2-FBS washing, 300. Mu.L of PBS + 2-FBS-resuspended cells were added, and the infection efficiency was examined by flow cytometry using uninfected T cells as a control, and the results are shown in FIG. 5, where the infected CAR-T cells had a clear positive cell population, indicating that the present invention successfully constructed 8 CAR-T cells expressing chimeric antigen receptors of different structures, in which the antigen-binding domain of the chimeric antigen receptor contained only CD22-28 antibody (corresponding to the cell marker CD22 (V28)) or CD22-29 antibody (corresponding to the cell marker CD22 (V29)), and the antigen-binding domain of the chimeric antigen receptor contained both CD22 and CD19 antibodies, but were ranked differently and labeled CD22 (V28) -CD19, CD22 (V29) -CD19, CD19-CD22 (V28), CD19-CD22 (V29), CD19- ε -CD22 (V28) - γ or CD19- ε -CD22 (V29) - γ, respectively.

Example 11

This example used 8 CAR-T cells prepared in example 9 to perform an in vitro toxicity assay comprising the following steps:

(1) Target cell inoculation:

tumor cells K562-luci (CD 19) preserved in this laboratory ^- CD22 ^- )、K562-CD19-luci(CD19 ⁺ CD22 ^- )、K562-CD22-luci(CD19 ^- CD22 ⁺ )、K562-CD19-CD22-luci(CD19 ⁺ CD22 ⁺ ) As the target cells, the concentration of the target cells was adjusted to 2X 10 ⁵ mL, inoculate 50 μ L to 96well plates;

(2) Effector cell inoculation:

the CAR-T cells prepared in example 9 and containing both CD19 and CD22 antibodies and control T (not lentivirus infected) cells were used as effector cells; CAR-T cells and control T cells were added to 96-well plates at a target ratio of 0.3;

each group was assigned 2 duplicate wells, and the average of the 2 duplicate wells was taken, where the experimental and control groups were as follows:

experimental groups: CAR-T + target cells;

control group: control T cells + target cells;

(3) After the effector cells and the target cells are co-cultured for 18h, steady-

The luciferase detection kit is used for detection, and the specific detection step refers to Steady-

The results of the luciferase assay kit instructions are shown in fig. 6A-6D, and the CAR-T cells constructed by the invention have high killing activity on CD22 and CD19 positive tumor cells, and have no killing effect on CD22 and CD19 negative cells, which indicates that the CAR-T cells constructed by the invention also have high specificity.

Example 12

This example detects CAR-T cytokine secretion.

1. Cell culture supernatant

The cell culture of example 11 with an effective target ratio of 1 was centrifuged at 400 Xg for 10min to remove the precipitate, and the supernatant was stored at-80 ℃ for examination.

2. Reagent preparation

The combined biological ELISA kit (the product numbers are respectively: human gamma interferon ELISA kit: EK180-96, human interleukin 2ELISA kit: EK102-96 and human tumor necrosis factor alpha (TNF-alpha) ELISA kit: EK 182-96) is used for detection, all reagents and samples are recovered to 25 ℃ before detection, 1 Xwashing liquid and 1 Xdetection buffer solution are prepared according to the use instructions, and the antibody is detected.

3. Standard and sample preparation

And (3) standard substance: use 5%1640 medium 2-fold dilution of the standard stock solution, for a total of 8 dilution gradients, including zero concentration.

Sample preparation: using 5%1640 medium to dilute the sample proportionally.

4. Detection step

(1) Soaking the enzyme label plate: adding 300 mu L of 1 Xwashing liquid, standing and soaking for 30s, removing the washing liquid, and patting the microporous plate on absorbent paper to dry;

(2) Adding a standard substance: adding 100 μ L of 2-fold diluted standard to the standard well, and adding 100 μ L of 5% medium to the blank well;

(3) Adding a sample: adding 100 mu L of cell culture supernatant into the sample hole;

(4) Adding a detection antibody: add 50 μ L of diluted detection antibody per well (1;

(5) And (3) incubation: incubating for 2h at 25 ℃ by using a sealing plate and a membrane sealing plate and oscillating at 300 rpm;

(6) Washing: discarding the liquid, adding 300 mu L of washing liquid into each hole, washing the plate for 6 times;

(7) And (3) adding enzyme for incubation: add 100 μ L of diluted horseradish peroxidase-labeled streptavidin per well (1;

(8) And (3) incubation: sealing the plate with a new sealing plate membrane, shaking at 300rpm, and incubating at 25 deg.C for 45min;

(9) Washing: repeating the step (6);

(10) Adding a substrate for color development: adding 100 μ L chromogenic substrate TMB into each well, keeping out of the sun, and incubating for 15min at 25 ℃;

(11) Adding a stop solution: adding 100 mu L of stop solution into each hole, and fully and uniformly mixing;

(12) And (3) detection reading: and performing dual-wavelength detection by using a microplate reader, measuring OD values at a maximum absorption wavelength of 450nm and a reference wavelength of 630nm, and subtracting the measured value of 630nm from the measured value of 450nm after calibration.

The secretion results of IL-2, TNF-alpha and IFN-gamma factors are respectively shown in figures 7-9, wherein the independent CAR-T cell culture is performed spontaneously, trace amounts of TNF-alpha, IL-2 and IFN-gamma factors are detected in the spontaneous and K562-luci and CAR-T cultures, and higher amounts of IL-2, TNF-alpha and IFN-gamma factors are detected in the K562-CD19-luci, K562-CD22-luci and K562-CD19-CD22-luci respectively and in the CAR-T culture, which indicates that the CAR-T cells constructed by the invention can release cytokines to kill CD19 and/or CD22 positive tumor cells, have high specificity and have no obvious cytokine secretion to CD19 and/or CD22 negative cells.

In conclusion, the anti-CD 22 antibody is prepared by screening, has high affinity and specificity, can effectively target a tumor antigen CD22, utilizes the anti-CD 22 anti-chimeric antigen receptor, and further prepares a chimeric antigen receptor cell, and the chimeric antigen receptor cell can efficiently kill tumor cells, can secrete various cytokines to play a killing function, and has high specificity.

The applicant states that the present invention is illustrated by the above examples to show the detailed method of the present invention, but the present invention is not limited to the above detailed method, that is, it does not mean that the present invention must rely on the above detailed method to be carried out. It should be understood by those skilled in the art that any modifications of the present invention, equivalent substitutions of the raw materials of the product of the present invention, and the addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.

SEQUENCE LISTING

<110> Huadao (Shanghai) biopharmaceutical Co., ltd

<120> anti-CD 22 antibody and application thereof

<130> 20211214

<160> 22

<170> PatentIn version 3.3

<210> 1

<211> 8

<212> PRT

<213> Artificial sequence

<400> 1

Gly Asp Thr His Ser Ser Tyr Cys

1 5

<210> 2

<211> 8

<212> PRT

<213> Artificial sequence

<400> 2

Gly Tyr Thr Asn Ser Arg Arg Tyr

1 5

<210> 3

<211> 7

<212> PRT

<213> Artificial sequence

<400> 3

Val Asp Ser Asp Gly Lys Gln

1 5

<210> 4

<211> 10

<212> PRT

<213> Artificial sequence

<400> 4

Ile Tyr Thr Gly Asp Gly Asp Ser Arg Thr

1 5 10

<210> 5

<211> 15

<212> PRT

<213> Artificial sequence

<400> 5

Ala Ala Ala Pro Trp Cys Tyr Arg Glu Ala Glu Asp Phe Thr Ile

1 5 10 15

<210> 6

<211> 18

<212> PRT

<213> Artificial sequence

<400> 6

Ala Ala Asp Val Trp Tyr His Gly Asp Trp Asn Asp Pro Lys Leu Tyr

1 5 10 15

Pro Tyr

<210> 7

<211> 25

<212> PRT

<213> Artificial sequence

<400> 7

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Ser Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser

20 25

<210> 8

<211> 25

<212> PRT

<213> Artificial sequence

<400> 8

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Ser Val Gln Ala Gly Gly

1 5 10 15

Ser Leu Thr Leu Ser Cys Ala Ala Ser

20 25

<210> 9

<211> 17

<212> PRT

<213> Artificial sequence

<400> 9

Leu Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ala

1 5 10 15

Phe

<210> 10

<211> 17

<212> PRT

<213> Artificial sequence

<400> 10

Met Ala Trp Phe Arg Gln Thr Pro Gly Lys Glu Arg Glu Gly Val Ala

1 5 10 15

Tyr

<210> 11

<211> 38

<212> PRT

<213> Artificial sequence

<400> 11

Ile His Ala Asp Ser Val Lys Gly Arg Phe Thr Gly Ser Arg Asp Asn

1 5 10 15

Thr Lys Asn Thr Leu Phe Leu Gln Met Asp Ser Leu Gln Leu Glu Asp

20 25 30

Thr Ala Met Tyr Tyr Cys

35

<210> 12

<211> 38

<212> PRT

<213> Artificial sequence

<400> 12

Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn

1 5 10 15

Ala Lys Gly Thr Val Asn Leu Gln Met Asn Ser Leu Gln Pro Gly Asp

20 25 30

Ser Ala Met Tyr Tyr Cys

35

<210> 13

<211> 11

<212> PRT

<213> Artificial sequence

<400> 13

Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser

1 5 10

<210> 14

<211> 121

<212> PRT

<213> Artificial sequence

<400> 14

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Ser Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Asp Thr His Ser Ser Tyr

20 25 30

Cys Leu Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val

35 40 45

Ala Phe Val Asp Ser Asp Gly Lys Gln Ile His Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Gly Ser Arg Asp Asn Thr Lys Asn Thr Leu Phe Leu

65 70 75 80

Gln Met Asp Ser Leu Gln Leu Glu Asp Thr Ala Met Tyr Tyr Cys Ala

85 90 95

Ala Ala Pro Trp Cys Tyr Arg Glu Ala Glu Asp Phe Thr Ile Trp Gly

100 105 110

Gln Gly Thr Gln Val Thr Val Ser Ser

115 120

<210> 15

<211> 127

<212> PRT

<213> Artificial sequence

<400> 15

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Ser Val Gln Ala Gly Gly

1 5 10 15

Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Arg

20 25 30

Tyr Met Ala Trp Phe Arg Gln Thr Pro Gly Lys Glu Arg Glu Gly Val

35 40 45

Ala Tyr Ile Tyr Thr Gly Asp Gly Asp Ser Arg Thr Tyr Tyr Ala Asp

50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Gly Thr

65 70 75 80

Val Asn Leu Gln Met Asn Ser Leu Gln Pro Gly Asp Ser Ala Met Tyr

85 90 95

Tyr Cys Ala Ala Asp Val Trp Tyr His Gly Asp Trp Asn Asp Pro Lys

100 105 110

Leu Tyr Pro Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser

115 120 125

<210> 16

<211> 363

<212> DNA

<213> Artificial sequence

<400> 16

gaagtgcagc tggtggaatc tggcggcgat agcgtgcagc ctggcggcag cctgagactg 60

agctgtgccg tgagcggcga tacccatagc agctattgtc tggcctggtt tagacaggcc 120

cctggcaaag aaagagaagg cgtggccttt gtggattccg atggaaaaca gattcatgcc 180

gatagcgtga aaggccggtt taccggctcc agagataata ccaaaaatac cctgtttctg 240

cagatggata gcctgcagct ggaagatacc gccatgtatt attgtgccgc cgccccttgg 300

tgttatagag aagccgaaga ttttaccatt tggggccagg gcacccaggt gaccgtgagc 360

agc 363

<210> 17

<211> 381

<212> DNA

<213> Artificial sequence

<400> 17

gaggtgcagc tggtggagag cggcggcgcc agcgtgcagg ccggcggcag cctgaccctg 60

agctgtgctg cctctggata cacaaattct agaagatata tggcctggtt tagacagacc 120

ccaggaaaag agagagaagg cgtggcttat atctatacag gcgatggaga ttctagaaca 180

tattatgccg atagcgtgaa gggcagattc acaattagca gagacaacgc caagggcacc 240

gtgaacctgc agatgaacag cctgcagccc ggcgacagcg ccatgtacta ctgcgccgcc 300

gacgtgtggt accacggcga ctggaacgac ccaaagctgt acccctactg ggggcagggc 360

acccaggtga ccgtgagcag c 381

<210> 18

<211> 21

<212> PRT

<213> Artificial sequence

<400> 18

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro

20

<210> 19

<211> 69

<212> PRT

<213> Artificial sequence

<400> 19

Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala

1 5 10 15

Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly

20 25 30

Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile

35 40 45

Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val

50 55 60

Ile Thr Leu Tyr Cys

65

<210> 20

<211> 112

<212> PRT

<213> Artificial sequence

<400> 20

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly

1 5 10 15

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr

20 25 30

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys

35 40 45

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys

50 55 60

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg

65 70 75 80

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala

85 90 95

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

100 105 110

<210> 21

<211> 185

<212> PRT

<213> Artificial sequence

<400> 21

Asp Gly Asn Glu Glu Met Gly Gly Ile Thr Gln Thr Pro Tyr Lys Val

1 5 10 15

Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Pro Gln Tyr Pro Gly

20 25 30

Ser Glu Ile Leu Trp Gln His Asn Asp Lys Asn Ile Gly Gly Asp Glu

35 40 45

Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp His Leu Ser Leu Lys Glu

50 55 60

Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr Val Cys Tyr Pro Arg Gly

65 70 75 80

Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu Tyr Leu Arg Ala Arg Val

85 90 95

Cys Glu Asn Cys Met Glu Met Asp Val Met Ser Val Ala Thr Ile Val

100 105 110

Ile Val Asp Ile Cys Ile Thr Gly Gly Leu Leu Leu Leu Val Tyr Tyr

115 120 125

Trp Ser Lys Asn Arg Lys Ala Lys Ala Lys Pro Val Thr Arg Gly Ala

130 135 140

Gly Ala Gly Gly Arg Gln Arg Gly Gln Asn Lys Glu Arg Pro Pro Pro

145 150 155 160

Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln Arg Asp Leu

165 170 175

Tyr Ser Gly Leu Asn Gln Arg Arg Ile

180 185

<210> 22

<211> 160

<212> PRT

<213> Artificial sequence

<400> 22

Gln Ser Ile Lys Gly Asn His Leu Val Lys Val Tyr Asp Tyr Gln Glu

1 5 10 15

Asp Gly Ser Val Leu Leu Thr Cys Asp Ala Glu Ala Lys Asn Ile Thr

20 25 30

Trp Phe Lys Asp Gly Lys Met Ile Gly Phe Leu Thr Glu Asp Lys Lys

35 40 45

Lys Trp Asn Leu Gly Ser Asn Ala Lys Asp Pro Arg Gly Met Tyr Gln

50 55 60

Cys Lys Gly Ser Gln Asn Lys Ser Lys Pro Leu Gln Val Tyr Tyr Arg

65 70 75 80

Met Cys Gln Asn Cys Ile Glu Leu Asn Ala Ala Thr Ile Ser Gly Phe

85 90 95

Leu Phe Ala Glu Ile Val Ser Ile Phe Val Leu Ala Val Gly Val Tyr

100 105 110

Phe Ile Ala Gly Gln Asp Gly Val Arg Gln Ser Arg Ala Ser Asp Lys

115 120 125

Gln Thr Leu Leu Pro Asn Asp Gln Leu Tyr Gln Pro Leu Lys Asp Arg

130 135 140

Glu Asp Asp Gln Tyr Ser His Leu Gln Gly Asn Gln Leu Arg Arg Asn

145 150 155 160

Claims

1. An anti-CD 22 antibody, wherein said anti-CD 22 antibody comprises a heavy chain variable region;

the amino acid sequence of CDR1 of the heavy chain variable region is the sequence shown in SEQ ID No. 1;

the amino acid sequence of CDR2 of the heavy chain variable region is the sequence shown in SEQ ID No. 3;

the amino acid sequence of CDR3 of the heavy chain variable region is the sequence shown in SEQ ID No. 5.

2. The anti-CD 22 antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region is the sequence shown in SEQ ID No. 14.

3. A nucleic acid molecule comprising a gene encoding the anti-CD 22 antibody of claim 1 or 2.

4. The nucleic acid molecule of claim 3, wherein said nucleic acid molecule is the sequence shown in SEQ ID No. 16.

5. A chimeric antigen receptor comprising a signal peptide, an antigen binding domain, a hinge region, a transmembrane domain, and a signaling domain;

the antigen binding domain comprises the anti-CD 22 antibody of claim 1 or 2.

6. The chimeric antigen receptor according to claim 5, wherein the signal peptide is a CD8a signal peptide.

7. The chimeric antigen receptor according to claim 5, wherein the antigen binding domain is an antigen binding domain composed of an anti-CD19 antibody and an anti-CD 22 antibody in series or an antigen binding domain composed of an anti-CD 22 antibody and an anti-CD19 antibody in series.

8. The chimeric antigen receptor according to claim 5, wherein the hinge region comprises a CD8a hinge region.

9. The chimeric antigen receptor according to claim 5, wherein the transmembrane domain comprises any one of a CD8a transmembrane region, a CD28 transmembrane region, or a DAP10 transmembrane region, or a combination of at least two thereof.

10. The chimeric antigen receptor according to claim 5, wherein the signaling domain comprises an immunoreceptor tyrosine activation motif.

11. The chimeric antigen receptor according to claim 10, wherein the signal transduction domain further comprises a co-stimulatory molecule comprising any one of or a combination of at least two of the 4-1BB, CD28 intracellular domains, OX40, ICOS or DAP10 intracellular domains.

12. The chimeric antigen receptor according to claim 5, wherein said chimeric antigen receptor comprises a first peptide chain obtained by fusing an anti-CD19 antibody and a CD3 epsilon and a second peptide chain obtained by fusing an anti-CD 22 antibody and a CD3 gamma, or said chimeric antigen receptor comprises a first peptide chain obtained by fusing an anti-CD 22 antibody and a CD3 epsilon and a second peptide chain obtained by fusing an anti-CD19 antibody and a CD3 gamma.

13. An expression vector comprising a gene encoding the chimeric antigen receptor of claim 5.

14. The expression vector of claim 13, wherein the expression vector is any one of a lentiviral vector, a retroviral vector or an adeno-associated viral vector comprising the gene encoding the chimeric antigen receptor of claim 5.

15. The expression vector of claim 14, wherein the expression vector is a lentiviral vector comprising a gene encoding the chimeric antigen receptor of claim 5.

16. A recombinant lentivirus comprising the expression vector of claim 13.

17. A chimeric antigen receptor immune cell, wherein said chimeric antigen receptor immune cell expresses the chimeric antigen receptor of claim 5.

18. The chimeric antigen receptor immune cell according to claim 17, characterized in that it comprises the expression vector of claim 13 and/or the recombinant lentivirus of claim 16.

19. The chimeric antigen receptor immune cell according to claim 17, wherein said chimeric antigen receptor immune cell comprises any one of T lymphocytes, B lymphocytes, NK cells, mast cells or macrophages or a combination of at least two thereof.

20. A pharmaceutical composition comprising the chimeric antigen receptor immune cell of claim 17.

21. The pharmaceutical composition of claim 20, further comprising a pharmaceutically acceptable excipient.

22. Use of the anti-CD 22 antibody of claim 1 or 2, the nucleic acid molecule of claim 3, the chimeric antigen receptor of claim 5, the expression vector of claim 13, the recombinant lentivirus of claim 16, the chimeric antigen receptor immune cell of claim 17, or the pharmaceutical composition of claim 20 in the preparation of a medicament for treating a tumor.

23. The use of claim 22, wherein the tumor is B-cell acute lymphoblastic leukemia.